Merck KGaA
Rating
Updated: Sep 17, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
A detailed description of the company is not yet available.
Latest News
2 months ago · seekingalpha.com
Merck KGaA (MKKGY) Q2 2026 Earnings Call TranscriptMerck KGaA (MKKGY) Q2 2026 Earnings Call Transcript
2 months ago · zacks.com
Merck KGaA (MKKGY) Misses Q2 Earnings EstimatesMerck KGaA (MKKGY) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.57 per share a year ago.
2 months ago · businesswire.com
Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical DevelopmentBAAR, Switzerland--(BUSINESS WIRE)--Evinova, a global leader in AI-native clinical development technology, today announced a new multi-year strategic collaboration to accelerate global clinical development with Merck KGaA, Darmstadt, Germany, a leading science and technology company. Merck KGaA, Darmstadt, Germany will adopt the end-to-end capabilities of the Evinova AI-Native platform covering all modules of study design, document authoring, and downstream automation to significantly reduce ti.
2 months ago · zacks.com
Merck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the UpgradeMerck KGaA (MKKGY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
3 months ago · zacks.com
Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 months ago · zacks.com
Merck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?Merck KGaA (MKKGY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
3 months ago · benzinga.com
Merck Germany Lands Bio-Techne In $11.3 Billion Cash DealMerck KGaA (OTC:MKKGY) (OTC:MKGAF) on Thursday agreed to acquire Bio-Techne Corporation (NASDAQ:TECH) in an all-cash transaction valued at approximately $11.3 billion, as the German science and technology company seeks to expand its presence across life science research, diagnostics, and bioprocessing markets.
3 months ago · barrons.com
Germany's Merck Is Buying Bio-Techne for $11.3 BillionBio-Techne stock jumps, with Germany's Merck KGaA buying the company at a 24% premium.
3 months ago · reuters.com
Germany's Merck to buy Bio-Techne for $73 per shareMerck KGaA has agreed to acquire biotech firm Bio-Techne Corp for $73 per share in cash, the German science and healthcare firm said in a statement on Thursday.
3 months ago · wsj.com
Germany's Merck to Buy Bio-Techne for $11 BillionMerck KGaA offered $73 a share in cash to buy Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier's closing price Wednesday.
Add to Watchlist
Select watchlists to add or remove MKKGY